Copaxone

Key drag for the Dr Reddy's is India business. Compared to its peers, it has a low revenue share in India and that too is majorly in the acute category

Natco gets a booster dose on favorable patent ruling in US

Natco and Mylan believe that they are the first companies to have filed a substantially complete abbreviated new drug application containing a Para-IV certification for a 3 times per week Glatiramer Acetate Injection 40 mg/mL, and expect 180 days of marketing exclusivity in the US.

Weakness in Sun Pharma a buying opportunity: IIFL

The pharma space has been in focus post Sun Pharma-Daiichi deal and the likelihood of a possible merger between Teva and Mylan globally. In an interview to CNBC-TV18, Abhishek Sharma of IIFL discusses his outlook on the sector and on specific companies.

Teva offers to buy out Mylan: What does it mean for Natco

Natco is engaged in a legal battle to launch a generic version of Teva's top-selling drug Copaxone, patent on which expires in September.

US Supreme Court rules for Teva over MS drug patent

US supreme court has suggested that Appeals court did not use the right approach in analyzing whether Teva's September 2015 patent is valid or not.

Natco Pharma at record high; partner Mylan files ANDA

"Marketing partner in the USA, Mylan Inc has filed an abbreviated new drug application (ANDA) for a three-times-a-week generic Copaxone (glatiramer acetate injection, 40 mg/ml) and has been accepted by the US Food and Drug Administration (US FDA)," said the company in its filing.

Patent win against Teva to boost revenues: Natco Pharma

Bhaskar Narayana, Finance Director & CFO, Natco Pharma is confident of maintaining the current growth rate in terms of margins going forward.

Natco Pharma surges further on patent case win against Teva

The main booster for the stock is its victory in a patent battle against Israeli drug-giant Teva Pharmaceuticals over USD 4 billion multiple Sclerosis drug Copaxone.

Natco Pharma at record high, jumps 8% on US court ruling

US Supreme Court justice declined a request from Teva for a stay of an appeals court ruling that would strip the company's USD 4 billion-a-year multiple sclerosis drug Copaxone of patent protection in 2014, rather than in 2015.

Natco loses patent case against Teva of anti-sclerosis drug

Natco Pharma Ltd has lost a patent litigation against Israel's Teva Pharmaceutical Industries Ltd in the US over multiple sclerosis treatment drug, Copaxone.

Natco may appeal US court ruling against Copaxone generic

Natco Pharma shares tumbled over 6% on Monday after a US court upheld Teva Pharmaceuticals' contention that the Indian drug maker's application for a generic version of Copaxone infringed all asserted claims of Teva, the world's largest generic drugs maker.

Natco Pharma to sell US pharma biz when opportunity knocks

Bhaskar Narayana, Finance Director & CFO, Natco Pharma said that he no longer sees synergies with SaveMart Pharmacy existing. The revenue being generated from SaveMart Pharmacy is USD 18 million.

Natco Pharma may sell US-based pharmacy store SaveMart

In an interview on CNBC-TV18, Bhaskar Narayana, finance director and chief financial officer at Natco Pharma said that synergies with the SaveMart Pharmacy exist no longer.